A recent clinical trial suggests that most breast cancer survivors who develop heart problems as a side effect of their treatment may not require lifelong medication for heart health. The findings offer a promising outlook for patients whose heart function has improved following cancer therapy, according to experts involved in the study.
The study, funded by the British Heart Foundation, monitored 90 women receiving care at four hospitals in the United Kingdom. These patients, predominantly in their 40s and 50s, had initially experienced reduced heart function attributed to their cancer treatment. Standard practice had recommended continued use of heart medications to prevent further deterioration. However, researchers found that nearly all participants—98 percent—who discontinued their heart drugs maintained stable heart function after one year. Only one woman exhibited a decline in her heart’s pumping ability during this period. Additionally, those who stopped the medication reported an improved quality of life.
Led by Professor Charlotte Manisty, head of clinical cardiovascular science at University College London, the trial’s results were published in the Heart Journal. Professor Manisty emphasized the significance of balancing the success of modern breast cancer therapies with their potential cardiac side effects. She stated that the study provides initial evidence indicating that heart failure treatments can be safely withdrawn in survivors whose cardiac function has returned to normal, provided they are closely monitored. According to her, these findings offer hope to both patients and clinicians for managing heart health post-cancer treatment.
One participant, Lucy Shepherd from Hertfordshire, described the trial’s impact on her life. Diagnosed with breast cancer at age 33, Shepherd’s heart function declined during her treatment, leading her to begin heart medication before restarting cancer therapy. Now 39, she expressed relief in being able to discontinue the medication as part of the trial. Shepherd noted that this change improved her quality of life, allowed her to regain trust in her body, and reduced her anxiety about ongoing treatment, even as she continues hormone therapy.
The researchers plan to follow the women over the next five years to track any long-term changes in cardiac health. Dr. Sonya Babu-Narayan of the British Heart Foundation commented that the results are encouraging for thousands of breast cancer survivors experiencing similar heart issues. While she called for further research and extended monitoring, she described the current findings as positive news for this patient population.
Overall, the study provides initial reassurance that heart medications may not need to be lifelong for many breast cancer survivors who have recovered cardiac function, potentially reducing treatment burden and improving quality of life.